EMPA-KIDNEY Trial Review: SGLT2 Inhibitors in Broad CKD

In this Nephrology Notebook episode, we review the EMPA-KIDNEY trial, a landmark randomized trial of empagliflozin in chronic kidney disease. We cover the clinical rationale, trial design, inclusion criteria, primary outcome, eGFR slope data, subgroup interpretation, safety profile, limitations, and practical prescribing logic. Special focus is given to what EMPA-KIDNEY added beyond earlier SGLT2 inhibitor kidney trials: patients without diabetes, patients with advanced CKD, and patients with lower albuminuria. Any patient case discussed is hypothetical and used only for clinical teaching. This video is for educational purposes only and is not individualized medical advice. Reference basis: EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2023;388:117-127. Key Points 1. EMPA-KIDNEY showed that empagliflozin reduced kidney disease progression or cardiovascular death in a broad CKD population. 2. The primary outcome occurred in 13.1% with empagliflozin versus 16.9% with placebo; hazard ratio 0.72. 3. EMPA-KIDNEY included many patients without diabetes and many with eGFR below 30. 4. Benefits were broadly consistent by diabetes status and eGFR category. 5. Lower-albuminuria subgroup hard-outcome estimates were less precise because fewer events occurred. 6. eGFR slope analyses supported slower chronic decline after the expected early dip. 7. Serious adverse events were similar overall, but SGLT2-specific risks still require counseling and monitoring. 8. Empagliflozin should be considered as a CKD risk-reduction option in appropriately selected patients, not as individualized blanket therapy.